Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anticancer Drug
Deguelin enhances leukemia cell chemosensitivity with active PI3K/AKT pathway
August 26th, 2005
Deguelin enhances leukemia cell chemosensitivity with an active PI3K/AKT pathway. "Activation of the phosphoinositide 3 kinase (PI3K)/Akt signaling pathway has been linked with resistance to chemotherapeutic drugs, and its downregulation, by means of PI3K inhibitors, lowers resistance to various types of therapy in tumor cell lines. "Recently, it has been reported that deguelin, a naturally occurring rotenoid, is a powerful inhibitor of PI3K," wrote investigators in Italy. "We investigated whether or not deguelin could enhance the sensitivity to chemotherapeutic drugs of human U937 leukemia cells and acute myeloid leukemia (AML)...
Source: Drug Week (2005-08-26)
|
